Product image of Neripar (Linagliptin) supplied by GNH India

Neripar

Active Ingredient:
Linagliptin
Origin:
EU

Neripar (Linagliptin)

Linagliptin, the active ingredient in Neripar, is a DPP-4 inhibitor presented as a tablet for oral use. It helps lower blood glucose in adults with type 2 diabetes mellitus. GNH India supplies Neripar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pharmapath Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is used to improve glycemic control in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels when combined with diet and exercise.
  • Monotherapy in type 2 diabetes: provides glucose‑lowering effect for patients inadequately controlled by lifestyle alone.
  • Combination therapy: used alongside metformin, sulfonylureas or insulin to achieve target HbA1c.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced hepatic glucose production and improved post‑prandial glucose control.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract infection symptoms.
  • Headache: transient mild to moderate pain.
  • Dizziness: occasional light‑headed sensation.
  • Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea.
  • Back pain: occasional musculoskeletal discomfort.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with vomiting.
  • Severe hypersensitivity: rash, angioedema or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: blistering skin disorder.
  • Severe allergic reactions: respiratory distress or shock.

Precautions & Warnings

Linagliptin should be used with clinical monitoring and awareness of patient‑specific factors.

  • Renal impairment: assess kidney function before initiation and periodically thereafter.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Elderly patients: monitor for hypoglycaemia when combined with insulin or sulfonylureas.
  • Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
  • Drug interactions: review concomitant medications for potential interactions.
  • Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Linagliptin may interact with several medicines that affect its plasma concentration or glycaemic response.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase linagliptin exposure.
  • Combination with insulin or sulfonylureas: heightened risk of hypoglycaemia.
  • Rifampin: may reduce linagliptin efficacy.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: monitor blood pressure and renal function.
  • Diuretics: observe electrolyte balance.
  • Warfarin: check INR regularly for potential anticoagulant effect changes.

Frequently Asked Questions

Neripar contains linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It is prescribed to improve glycaemic control when diet, exercise, or other oral antidiabetic agents are insufficient.

Linagliptin blocks the DPP‑4 enzyme, which normally degrades incretin hormones. By preserving incretins such as GLP‑1 and GIP, it enhances glucose‑dependent insulin secretion, reduces glucagon release, and lowers hepatic glucose output, leading to better blood‑sugar regulation.

The specific dose of Neripar is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neripar (linagliptin) is a once‑daily DPP‑4 inhibitor that does not require dose adjustment in mild to moderate renal impairment, unlike some alternatives. Its efficacy in lowering HbA1c is comparable to other agents in the class, while its safety profile is similar, with low risk of hypoglycaemia when used alone.

Neripar tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Neripar is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events, though rare, include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Neripar is contraindicated in patients with a known hypersensitivity to linagliptin or any component of the formulation. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnancy unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT